Corvus Pharmaceuticals (CRVS) investor relations material

Study overview and design

• Phase 1 randomized, placebo-controlled, blinded trial in moderate-to-severe atopic dermatitis, enrolling 72 adults who failed prior topical or systemic therapy, across four cohorts with 4–8 weeks of oral soquelitinib or placebo and up to 90 days of follow-up.

• Patient demographics and baseline disease severity were well balanced between active and placebo groups.

• No concomitant topical steroids allowed; prior systemic therapy permitted; 14 U.S. sites participated.

• 35% of patients had received prior systemic therapy, including treatment-resistant cases.

Efficacy results

• Dose-dependent, rapid, and deep clinical responses observed, with EASI75 rates up to 75%, EASI90 up to 25%, and IGA 0/1 up to 33% at highest dose and longest duration.

• Mean EASI reduction reached 72% at 8 weeks (200 mg BID), outperforming placebo.

• Durable responses maintained 30–90 days after treatment discontinuation, with no rebound or need for rescue medication.

• Efficacy observed in patients with prior systemic therapy, including those resistant to other treatments.

Safety profile

• No severe or serious adverse events reported; adverse events were mild (grade 1–2), balanced between groups, and did not require dose modification or discontinuation.

• No clinically significant lab abnormalities, infection signals, or cases of conjunctivitis; most common adverse events were headache and mild gastrointestinal symptoms.